| 1 |
IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis
James Edward Vince, Wendy Wei-Lynn Wong, Nufail R. Khan et al. · Cell
Open access |
Nov 2007 |
1,071 |
| 2 |
Reproducibility in Science
C. Glenn Begley, John P. A. Ioannidis · Circulation Research
|
31 Dec 2014 |
1,070 |
| 3 |
RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL
Kate E. Lawlor, Nufail R. Khan, Alison Mildenhall et al. · Nature Communications
Open access |
18 Feb 2015 |
655 |
| 4 |
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Sabrina Paganoni et al. · New England Journal of Medicine
Open access |
2 Sep 2020 |
542 |
| 5 |
A Novel Mutation in the Cystic Fibrosis Gene in Patients with Pulmonary Disease but Normal Sweat Chloride Concentrations
William Edward Highsmith, Lauranell H. Burch, Zhaoqing Zhou et al. · New England Journal of Medicine
Open access |
13 Oct 1994 |
443 |
| 6 |
Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis
George Trichonas, Yusuke Murakami, Aristomenis Thanos et al. · Proceedings of the National Academy of Sciences
Open access |
22 Nov 2010 |
315 |
| 7 |
24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial
Hilkka S. Soininen et al. · The Lancet Neurology
Open access |
30 Oct 2017 |
247 |
| 8 |
TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1–TRAF2 complex to sensitize tumor cells to TNFα
James Edward Vince, Diep Chau, Bernard Andrew Callus et al. · The Journal of Cell Biology
Open access |
7 Jul 2008 |
238 |
| 9 |
Six red flags for suspect work
C. Glenn Begley · Nature
Open access |
21 May 2013 |
233 |
| 10 |
Donanemab: Appropriate use recommendations
G D Rabinovici, D. J. Selkoe, Suzanne Elizabeth Schindler et al. · The Journal of Prevention of Alzheimer s Disease
Open access |
29 Mar 2025 |
228 |
| 11 |
Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes
Jong J. Kirn, Mark L. Bagarazzi, Neil N. Trivedi et al. · Nature Biotechnology
|
Jul 1997 |
221 |
| 12 |
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
BRIAN A. LAWLOR et al. · PLoS Medicine
Open access |
24 Sep 2018 |
207 |
| 13 |
Aducanumab: Appropriate Use Recommendations Update
Jeffrey L. Cummings, Gil D. Rabinovici, Alireza Atri et al. · The Journal of Prevention of Alzheimer s Disease
Open access |
30 Mar 2022 |
197 |
| 14 |
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia
Gabriela Brumatti et al. · Science Translational Medicine
Open access |
18 May 2016 |
189 |
| 15 |
Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis
Sabrina Paganoni et al. · Muscle & Nerve
Open access |
16 Oct 2020 |
185 |
| 16 |
Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models
Christopher A. Benetatos et al. · Molecular Cancer Therapeutics
|
22 Feb 2014 |
180 |
| 17 |
Report of the task force on designing clinical trials in early (predementia) AD
Paul S. S Aisen et al. · Neurology
Open access |
23 Dec 2010 |
173 |
| 18 |
Smac Mimetics Activate the E3 Ligase Activity of cIAP1 Protein by Promoting RING Domain Dimerization
Rebecca Feltham, Bodhi Bettjeman, Rhesa Budhidarmo et al. · Journal of Biological Chemistry
Open access |
10 Mar 2011 |
169 |
| 19 |
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
Jinping Wang, Veronika Logovinsky, Suzanne B. Hendrix et al. · Journal of Neurology Neurosurgery & Psychiatry
Open access |
23 Mar 2016 |
164 |
| 20 |
Robust research: Institutions must do their part for reproducibility
C. Glenn Begley, Alastair Mitchell Buchan, Ulrich Dirnagl · Nature
Open access |
Sep 2015 |
164 |
| 21 |
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study
Merçé Boada, Oscar L. López, Javier Olazarán et al. · Alzheimer s & Dementia
Open access |
27 Jul 2020 |
145 |
| 22 |
Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force
Bruno J. Vellas et al. · Alzheimer s & Dementia
|
26 Jun 2013 |
145 |
| 23 |
36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease
Hilkka S. Soininen, Alina Solomon, Pieter Jelle Visser et al. · Alzheimer s & Dementia
Open access |
13 Sep 2020 |
139 |
| 24 |
A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma
Ravi K. Amaravadi, Russell J. Schilder, Lainie P. Martin et al. · Molecular Cancer Therapeutics
|
2 Sep 2015 |
135 |
| 25 |
The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort
Pierre N. Tariot et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions
Open access |
2018 |
131 |
| 26 |
An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease
Jessica B. S. Langbaum, Suzanne B. Hendrix, Napatkamon Ayutyanont et al. · Alzheimer s & Dementia
Open access |
21 Apr 2014 |
128 |
| 27 |
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease
Cristina López López, Pierre N. Tariot, Angelika Caputo et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions
Open access |
2019 |
119 |
| 28 |
Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis
Gregor Ebert, Cody C. Allison, Simon Preston et al. · Proceedings of the National Academy of Sciences
Open access |
20 Apr 2015 |
118 |
| 29 |
Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2
Maurice Darding, Rebecca Feltham, Tencho Tenev et al. · Cell Death and Differentiation
Open access |
18 Feb 2011 |
106 |
| 30 |
The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach
Richard Isaacson, Christine Anne Ganzer, Hollie Hristov et al. · Alzheimer s & Dementia
Open access |
13 Nov 2018 |
105 |
| 31 |
The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Clemens Krepler, Srinivas K. Chunduru, Molly B. Halloran et al. · Clinical Cancer Research
Open access |
12 Feb 2013 |
104 |
| 32 |
Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics
Najoua Lalaoui et al. · Cancer Cell
Open access |
Feb 2016 |
102 |
| 33 |
Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus
Gregor Ebert, Simon Preston, Cody C. Allison et al. · Proceedings of the National Academy of Sciences
Open access |
20 Apr 2015 |
96 |
| 34 |
Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease
Roos J. Jutten, Kathryn V. Papp, Suzanne B. Hendrix et al. · Alzheimer s & Dementia
Open access |
10 Sep 2022 |
91 |
| 35 |
Challenges in developing Geroscience trials
Yves Rolland et al. · Nature Communications
Open access |
19 Aug 2023 |
90 |
| 36 |
Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Craig M. McDonald et al. · The Lancet
Open access |
Mar 2022 |
86 |
| 37 |
FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
Marwan Noel Sabbagh, Suzanne B. Hendrix, John Harrison · Alzheimer s & Dementia Translational Research & Clinical Interventions
Open access |
21 Dec 2018 |
84 |
| 38 |
Individualized clinical management of patients at risk for Alzheimer's dementia
Richard Isaacson et al. · Alzheimer s & Dementia
Open access |
30 Oct 2019 |
79 |
| 39 |
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
Alireza Atri, Suzanne B. Hendrix, Vojislav Pejović et al. · Alzheimer s Research & Therapy
Open access |
10 Mar 2015 |
75 |
| 40 |
Implementation of mechanism of action biology-driven early drug development for children with cancer
Andrew D.J. Pearson et al. · European Journal of Cancer
Open access |
Jun 2016 |
72 |
| 41 |
Prevention trials in Alzheimer's disease: An EU-US task force report
Bruno J. Vellas, Paul S. S Aisen, Cristina Matos Sampaio et al. · Progress in Neurobiology
|
11 Sep 2011 |
68 |
| 42 |
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial
Sabrina Paganoni et al. · Journal of Neurology Neurosurgery & Psychiatry
Open access |
16 May 2022 |
67 |
| 43 |
Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study
Hui Jing Yu, Samuel P. Dickson, Pei‐Ning Wang et al. · EBioMedicine
Open access |
29 Jun 2023 |
66 |
| 44 |
CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT”
Susan R. Abushakra, Anton P. Porsteinsson, B. Vellas et al. · The Journal of Prevention of Alzheimer s Disease
Open access |
2016 |
66 |
| 45 |
Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report
Randall John Bateman, Kaj Blennow, Rachelle Smith Doody et al. · The Journal of Prevention of Alzheimer s Disease
Open access |
Jul 2019 |
65 |
| 46 |
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
S P Dickson, Alette M. Wessels, S.A. Dowsett et al. · The Journal of Prevention of Alzheimer s Disease
Open access |
27 Apr 2023 |
60 |
| 47 |
Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo
Leslie R. Coney, Bin Wang, Kenneth E. Ugen et al. · Vaccine
|
Dec 1994 |
60 |
| 48 |
Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways
Maria C. Tanzer, Nufail R. Khan, James A. Rickard et al. · Cell Death and Differentiation
Open access |
20 Jan 2017 |
59 |
| 49 |
Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL
Goodwin G. Jinesh, Srinivas K. Chunduru, Ashish M. Kamat · Journal of Leukocyte Biology
Open access |
19 Apr 2012 |
59 |
| 50 |
Regulation of ubiquitin transfer by XIAP, a dimeric RING E3 ligase
Yoshio Nakatani, Torsten Kleffmann, Katrin Linke et al. · Biochemical Journal
|
3 Jan 2013 |
59 |